8 completed. 8 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 8 |
| Phase 2 | 1 | Completed 1 |
Follow beta-lapachone: new trials by email Literature Review of beta-lapachone trials Research Report on beta-lapachone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers MB12066 200mg, Placebo - Metabolic Syndrome | Phase 1 | Completed | Yungjin Pharm. Co., Ltd. | 11 | 2015-01-01 | 2017-12-21 |
| Clinical Trial of ARQ 761 in Advanced Solid Tumors ARQ 761, ARQ 761 Weekly Administration, Bi-Weekly Administration of ARQ 761 - Solid Tumors | Phase 1 | Completed | University of Texas Southwestern Medical Center | 91 | 2011-12-29 | 2020-03-17 |
| Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers MB12066, Placebo - Metabolic Syndrome, Obesity | Phase 1 | Completed | Yungjin Pharm. Co., Ltd. | 40 | 2011-04-01 | 2017-12-21 |
| Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers MB12066 - Metabolic Syndrome, Obesity | Phase 1 | Completed | Yungjin Pharm. Co., Ltd. | 50 | 2010-07-01 | 2018-06-27 |
| An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors ARQ 501 - Advanced Solid Tumors | Phase 1 | Completed | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 9 | 2007-08-01 | 2011-10-19 |
| An Extension Study for Patients Previously Treated With ARQ 501 ARQ 501 - Cancer | Phase 1 / Phase 2 | Completed | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 1 | 2006-12-01 | 2013-02-28 |
| ARQ 501 in Combination With Docetaxel in Patients With Cancer ARQ 501 - Carcinoma | Phase 1 | Completed | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 50 | 2004-12-01 | 2009-04-28 |
| ARQ 501 in Subjects With Cancer ARQ 501 - Cancer | Phase 1 | Completed | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 80 | 2003-09-01 | 2009-04-28 |
Metabolic Syndrome (3) · Neoplasms (3) · Obesity (3) · Carcinoma (1) · Neoplasm Metastasis (1)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (4) · Yungjin Pharm. Co., Ltd. (3) · University of Texas Southwestern Medical Center (1)
United States (5) · South Korea (2)
C. Casey Cunningham, MD (2) · Kyung-Sang Yu, Professor (2) · David E Gerber, MD (1) · Geoffrey I Shapiro, MD (1) · Geoffrey Shapiro, MD, PhD (1) · Neil Nathan Senzer, MD (1)